News · 26 weeks125+33%
2026-03-012026-08-23
Mix5490d
- Other23(43%)
- Insider18(33%)
- SEC Filings6(11%)
- Dividends3(6%)
- Analyst2(4%)
- Earnings2(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by Chairman & CEO Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- PRPfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines AgencySubmission based on favorable efficacy and safety results from Phase 3 VALOR trial Pfizer Inc. (NYSE:PFE) and Valneva SE (NASDAQ:VALN, PARIS:VLA) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, the companies’ 6-valent outer surface protein A (OspA)-based Lyme disease vaccine candidate and will begin its assessment of the application. The application is based on encouraging efficacy of more than 70% observed in the Phase 3 VALOR "Vaccine Against Lyme for Outdoor Recreationists" clinical trial (NCT05477524), which investigated whether the vaccine candidate, PF-07307405, prevented Lyme disease cases in
- SECSEC Form 13F-HR filed by Pfizer Inc.13F-HR - PFIZER INC (0000078003) (Filer)
- INSIDERChairman & CEO Bourla Albert bought $1,000,920 worth of shares (38,000 units at $26.34), increasing direct ownership by 10% to 429,173 units (SEC Form 4)4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSVP & Controller Damico Jennifer B. sold $83,261 worth of shares (3,278 units at $25.40), decreasing direct ownership by 10% to 28,611 units (SEC Form 4)4 - PFIZER INC (0000078003) (Issuer)
- INSIDERDirector Blaylock Ronald E bought $998,821 worth of shares (39,231 units at $25.46), increasing direct ownership by 142% to 66,938 units (SEC Form 4)4 - PFIZER INC (0000078003) (Issuer)
- INSIDERDirector Buckley Mortimer J bought $960,369 worth of shares (37,632 units at $25.52) (SEC Form 4)4 - PFIZER INC (0000078003) (Issuer)
- PRNYSE Content Update: ADI to Make NYSE Trading Debut After Spin-OffNYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, Aug. 4, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on August 4thInvestors are weaving through the latest batch of earnings and new developments in the Middle East.Caterpillar (NYSE:CAT), McDonald's (NYSE:MCD), and Pfizer (NYSE:PFE) headlined this morning's slate of earnings reports.As of 8 a.m. ET, ICE Brent Crude is trading at $81 a barrel after President Trump said this is the
- SECSEC Form 10-Q filed by Pfizer Inc.10-Q - PFIZER INC (0000078003) (Filer)
- SECPfizer Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PFIZER INC (0000078003) (Filer)
- PRPfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue GuidanceFocused Execution Drove 18% Operational Revenue Growth of Launched and Acquired Products(1) Advancing Robust Late-Stage Pipeline, with Several Key Pivotal Readouts Expected Over Next 12 Months Announces Expansion of Productivity Enhancement Initiatives Pfizer Inc. (NYSE:PFE) reported financial results for the second quarter of 2026 and raised its full-year 2026 Revenue guidance by $500 million at the midpoint while reaffirming guidance(2) for Adjusted(3) diluted EPS, which absorbs an impact of approximately $0.10 related to the Innovent Biologics, Inc. transaction. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "Pfizer had another strong quarter, deliver
- INSIDERSEC Form 4 filed by Chairman & CEO Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- PRPfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental VitiligoTwo pivotal studies of LITFULO™ (ritlecitinib) in nonsegmental vitiligo met their co-primary endpoints, showing significant improvement in facial and total repigmentation versus placebo at Week 52 LITFULO was studied in the largest Phase 3 program to date evaluating an oral systemic therapy for nonsegmental vitiligo and has the potential to be a new treatment option for adults Pfizer Inc. (NYSE:PFE) today announced positive topline results from two Phase 3 trials evaluating the efficacy and safety of LITFULO once daily in patients with both active and stable nonsegmental vitiligo (NSV) and who had a broad range of disease severity. The TRANQUILLO study included patients aged 12 years
- PREuropean Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European UnionData indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the Pfizer-BioNTech COVID-19 vaccines distributed globallyVaccine demonstrates a favorable safety and efficacy profile Shipping will begin soon to ensure rapid access of this season’s vaccine NEW YORK and MAINZ, GERMANY, July 29, 2026 — Pfizer Inc. (NYSE:PFE, "Pfizer")) and BioNTech SE (NASDAQ:BNTX, "BioNTech")) announced today that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for activ
- PREuropean Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European UnionData indicate that the 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, induces a strong immune response against contemporary circulating and emerging lineages More than five billion doses of the Pfizer-BioNTech COVID-19 vaccines distributed globally Vaccine demonstrates a favorable safety and efficacy profile Shipping will begin soon to ensure rapid access of this season’s vaccine Pfizer Inc. (NYSE:PFE, "Pfizer")) and BioNTech SE (NASDAQ:BNTX, "BioNTech")) announced today that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent COVID-1
- PRFDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate CancerSupplemental application aims to expand use to men with HRR gene-mutated metastatic castration-sensitive prostate cancer Filing supported by Phase 3 TALAPRO-3 data demonstrating greater than 50% improvement in radiographic progression-free survival, with consistent benefit across BRCA and non-BRCA HRR gene alterations Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in men with homologous recombination re
- INSIDERSEC Form 4 filed by Chairman & CEO Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- PRAM Best Affirms Credit Ratings of Blue Whale Re Ltd.AM Best has affirmed the Financial Strength Rating of A (Excellent) and the Long-Term Issuer Credit Rating of "a+" (Excellent) of Blue Whale Re Ltd. (Blue Whale) (Burlington, VT). The outlook of these Credit Ratings (ratings) is stable.The ratings reflect Blue Whale’s balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, neutral business profile and appropriate enterprise risk management (ERM).The ratings also reflect Blue Whale’s function as the only captive insurer for Pfizer Inc. (Pfizer) (NYSE:PFE), a global pharmaceutical company. As Blue Whale insures or reinsures Pfizer’s international employee benefits and global property exposure
- INSIDERSEC Form 4 filed by Chairman & CEO Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- PRU.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin EligibilityFirst and only treatment regimen for adults with MIBC, regardless of cisplatin eligibility, representing a platinum-free potential standard of care Broadened approval supported by Phase 3 EV-304 data showing a nearly 50% reduction in the risk of tumor recurrence, progression or death, and a 35% reduction in the risk of death, versus standard of care in cisplatin-eligible patients Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus the PD-1 inhibitor, Keytruda® (pembro
- ANALYSTPfizer downgraded by HSBC Securities with a new price targetHSBC Securities downgraded Pfizer from Buy to Hold and set a new price target of $28.00
- INSIDERSEC Form 4 filed by Chairman & CEO Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Director Buckley Mortimer J4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Director Echevarria Joseph4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Director Narayen Shantanu4 - PFIZER INC (0000078003) (Issuer)
PFE FAQ
6 questionsWhat does Pfizer Inc. do?
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and...Where does PFE stock trade?
Pfizer Inc. (PFE) is listed on NYSE.What sector and industry is PFE in?
Pfizer Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PFE?
Pfizer Inc. has had 8 recent analyst actions on file. The most recent action was from HSBC Securities: Hold with a $2800.00 price target on 2026-07-06. Recent price targets range from $2500.00 to $3500.00.What companies are similar to PFE?
Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), NVS (Novartis AG), AZN (AstraZeneca PLC), SNY (Sanofi). Compare PFE side-by-side with any of them on Quantisnow.How can I track PFE on Quantisnow?
Quantisnow aggregates Pfizer Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PFE to receive live email and push alerts on every new disclosure.